NCT06436183

A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

A Phase 2a, Multicenter, Randomized, Double-blind, 16-week Placebo-controlled Study With an Open Label Extension to Evaluate the Efficacy and Safety of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 62 (actual)
• Sponsor: Apollo Therapeutics Ltd · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety of camoteskimab in adults with moderate to severe AD.

Detailed description

This study contains two parts: Parts 1 and Part 2. Part 1 (Blinded Period): Eligible patients will be randomized in a 1:1:1 ratio to receive either camoteskimab dose 1, camoteskimab dose 2 or placebo. Part 2 (Extension Period): In part 2, all participants will receive camoteskimab.

Conditions

• Atopic Dermatitis
• Atopic
• Dermatitis
• Dermatologic Disease
• Eczema
• Eczema Atopic Dermatitis
• Eczema, Atopic

Interventions

Type	Name	Description
DRUG	Camoteskimab	Drug Product
DRUG	Placebo	Inactive substance

Timeline

• Start date: 2024-05-01
• Primary completion: 2025-03-26
• Completion: 2025-08-12
• First posted: 2024-05-30
• Last updated: 2025-09-18

Locations

35 sites across 2 countries: United States, Canada

Regulatory

• FDA-regulated drug study